pdatanews

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

Yes at 81% and No at 19% on Kalshi as of 20:47 UTC on 20 Nov 2026.

Kalshi·Finance
United States
marketsingle market
Yes 81¢
No 19¢

If the FDA's decision on Tozorakimab by AstraZeneca on or before March 31, 2027 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

a full approval or an accelerated approval · prices over time
−24h
now
volume · 24h windows
no volume history

This is a single yes or no market on Kalshi in the finance category and it asks: What will the FDA's decision be on Tozorakimab by AstraZeneca on or before March 31, 2027? Over the last day Yes rose eight points and the market shows a spread of eight points between the best bid and ask. Trading on Kalshi is due to end on 1 April 2027 and Kalshi-reported volume is 122 contracts over the last day and 431 contracts since this finance market opened. This market is tracked by pdata.world next to twenty-four related events on Kalshi, Polymarket and Manifold including the Polymarket event titled FDA approves Retatrutide this year. Price history for this Kalshi finance market is available from pdata.world as JSON and through its MCP server.

similar markets

suggested by pdata